| Responsibility | |
| Pathogenesis | Pathogenesis of different tissue involvements in PsA. Pathogenesis of axial disease. Microbiome relationship to disease onset and progression. Prediction markers of response on synovial histopathology. Identification of new therapeutic targets. Understanding the biopathology of treatment-refractory PsA. Genetics of PsA.
|
| Very early PsA | Biomarkers for pre-PsA. Defining screening strategies for PsA among patients with psoriasis: is screening needed, and if so in which populations, how and when? Criteria for early diagnosis of PsA and role of imaging. Prevention of progression from psoriasis to PsA: pre-PsA therapy/interception (efficacy of DMARDs in preventing progression from Pso to PsA). Window of opportunity studies.
|
| Drug ordering/response prediction and biomarkers | Research on the effect of sex on treatment choices, treatment efficacy and treatment maintenance. Incorporating ultrasonography in decision-making. Biomarkers for prediction of disease and response. Prediction of response with genetics and polygenetics.
|
| Prognosis | Prognostic factors of progressive disease, structural damage and unfavourable functional outcomes. Predicting response to treatment (predicting response to NSAIDs, to csDMARDs, to the different bDMARDs, to tsDMARDs). Prognosis of early-onset (juvenile) PsA.
|
| First DMARD choices | Biosimilars vs methotrexate as first choice—strategy trials. Comparing direct and indirect costs, efficacy, side effects in employed, early, severe, bio-naïve PsA patient groups treated with methotrexate or biosimilars. Is there any advantage of using methotrexate over biosimilars in this group?
|
| Outcomes in PsA | Development/validation of composite scores of disease activity in PsA. Consensus on core outcomes in PsA trials. Coprimary outcomes for skin and joints. Efficacy of apremilast on structural changes. Drug-free remission as an outcome in PsA.
|
| Treatments | |
| Contextual factors in PsA | |
| Safety | Differential JAKi safety in PsA and across drugs. Tyrosine-kinase inhibition safety in PsA. Long-term safety trials in PsA.
|
| Axial PsA | Pathogenesis of axial PsA vs axSpA. Criteria for differentiation and overlap between axSpA and PsA. JAKis in axial PsA. Assessment of spinal disease: defining the similarities and differences with axSpA.
|
| Comorbidities | Impact of comorbidities on drug choice. Effect of metabolic intervention on disease activity. Effect of different DMARDs on cardiovascular risk. Influence of non-pharmacological interventions on multimorbidity. Entheseal PsA: overlap with widespread pain syndrome and role of imaging in the diagnosis. Treatment of pain which does not respond to usual therapies. Fatigue in PsA. Unravelling complexities of difficult-to-manage PsA.
|
| Switches | |